Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Therapeutic Potential
100%
Treatment Decisions
100%
Cost-effectiveness Analysis
100%
New Therapeutics
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Enzalutamide
100%
Quality-adjusted Life Years
83%
Abiraterone
83%
Placebo
50%
Cabazitaxel
50%
Placebo Groups
33%
Survival Rate
33%
Willingness-to-pay Threshold
33%
Clinical Trials
16%
Adverse Effects
16%
Further Analysis
16%
Treatment Options
16%
Seizure
16%
Prostate Cancer Patients
16%
Cost-effectiveness
16%
Neutropenia
16%
Sensitivity Analysis
16%
Life Expectancy
16%
Cardiac Events
16%
Severity Index
16%
Net Benefit
16%
Cost Analysis
16%
Drug Costs
16%
Societal Perspective
16%
Probabilistic Sensitivity Analysis
16%
Health Utility
16%
Chance Node
16%
Benefit Evaluation
16%
Decision Tree Model
16%
Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
100%
Castration Resistant Prostate Cancer
100%
Enzalutamide
100%
Placebo
83%
Quality Adjusted Life Year
83%
Abiraterone
83%
Cabazitaxel
50%
Survival Rate
33%
Clinical Trial
16%
Adverse Effect
16%
Epileptic Seizure
16%
Life Expectancy
16%
Neutropenia
16%
Treatment Option
16%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Enzalutamide
100%
Placebo
83%
Abiraterone
83%
Cabazitaxel
50%
Survival Rate
33%
Clinical Trial
16%
Neutropenia
16%
Life Expectancy
16%